Tag: pathways

New zoning laws set to expand placement of manufactured homes statewide, effective July 1

Plumbing contractors in 2025 across the United States face rising costs, tighter lending standards, and limited access to traditional credit. ROK Financial’s expansion of no credit check business loan programs responds to growing demand for flexible financing, offering contractors new pathways to secure working capital and sustain growth despite credit challenges.

Demand for the best HVAC business loans for bad credit in 2025 is climbing nationwide as ROK Financial expands no credit check financing programs, offering heating and cooling contractors faster access to working capital amid rising costs and tighter credit standards.

ROK Financial announces new loan pathways for pool and spa contractors heading into the 2025 season. By offering no credit check financing, fast approvals, and expanded loan ranges, the company addresses growing demand among small business owners with fair or poor credit histories. This initiative responds to the sharp rise in alternative lending searches and the increased pressure on contractors seeking reliable capital access as traditional banks tighten standards.

Demand for cannabis business financing in 2025 is reaching new levels as licensed operators search for reliable capital outside of traditional banks. ROK Financial has expanded access with no credit check loan options, addressing the growing need for small business funding solutions that work for owners with bad credit while staying aligned with state regulations and industry compliance.

The best no credit check business financing options in 2025 are gaining momentum as small business owners face tighter traditional lending standards and rising uncertainty in the economy. ROK Financial is meeting this demand with flexible loan programs, instant pre-approvals, and expanded access to capital for entrepreneurs across industries. By offering a range of solutions — from working capital and SBA loans to equipment and real estate financing — the company reflects a larger movement toward credit-independent funding that aligns with modern business needs.

Virtual Events Include Investor Webinar and Presentation at Emerging Growth Conference 85

SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) -- Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company’s innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic anemia, a rare orphan indication, Regen BioPharma is evaluating expanded applications for this groundbreaking therapy in markets poised for significant growth.

First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profile